Two Cheers For Panacea, Will It Get Three?

$24.3m Award For Easyfive-TT

30 Dec 2019

Promising data from Phase I clinical trials of a dengue vaccine and a $24.3m award by UN agencies for its Easyfive-TT pentavalent vaccine bode well for Panacea Biotec, but are they enough to turn the company’s fortunes around?

Happy Biz Team — Time For Celebrations At Panacea? • Source: Shutterstock

Loss-making Panacea Biotec Ltd. could find reason for cheer as initial data from a Phase I trial for a dengue vaccine licensed from the National Institutes of Health (NIH) appeared promising and United Nations (UN) agencies awarded the Indian company a $24.3m (over INR1.7bn) award for EasyfiveTT, its pentavalent vaccine.

Panacea, which produces pharmaceutical formulations apart from vaccines, is one among three Indian firms that the NIH had licensed its dengue candidate TetraVax-DV to, the others being Serum Institute...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Angelini Advances Brain Health Ambitions With GRIN Pact

27 May 2025

• By Kevin Grogan

The Italian drugmaker gets rights to Phase III-ready asset radiprodil.

Sweden’s Hansa Slims Down Ahead of Key Readouts

27 May 2025

• By Kevin Grogan

New CEO Renée Aguiar-Lucander is marking her mark.

Gilead Ready To Go After Hepatitis D Again

26 May 2025

• By Joseph Haas

Following an FDA complete response in 2022, Gilead is getting ready to refile bulevirtide for hepatitis D. The drug already is approved in the EU, UK and elsewhere.

Progress In The Effort To Improve Outcomes In SCLC

26 May 2025

• By Jessica Merrill

Several drug makers are working to bring new advances to small-cell lung cancer, a fast-growing cancer with limited treatment options.

Pipeline Watch: 12 Approvals And 26 Phase III Readouts

26 May 2025

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.